Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS-CoV-2 Neutralizing Antibodies

Abigail Vanderheiden, Venkata Viswanadh Edara, Katharine Floyd, Robert C. Kauffman, Grace Mantus, Evan Anderson, Nadine Rouphael, Sri Edupuganti, Pei Yong Shi, Vineet D. Menachery, Jens Wrammert, Mehul S. Suthar

Research output: Contribution to journalArticlepeer-review

27 Scopus citations

Abstract

SARS-CoV-2 is a recently emerged human coronavirus that has escalated to a pandemic. There are currently no approved vaccines for SARS-CoV-2, which causes severe respiratory illness or death. Defining the antibody response to SARS-CoV-2 will be essential for understanding disease progression, long-term immunity, and vaccine efficacy. Here we describe two methods for evaluating the neutralization capacity of SARS-CoV-2 antibodies. The basic protocol is a focus reduction neutralization test (FRNT), which involves immunostaining infected cells with a chromogen deposit readout. The alternate protocol is a modification of the FRNT that uses an infectious clone−derived SARS-CoV-2 virus expressing a fluorescent reporter. These protocols are adapted for use in a high-throughput setting, and are compatible with large-scale vaccine studies or clinical testing.

Original languageEnglish (US)
Article numbere116
JournalCurrent Protocols in Immunology
Volume131
Issue number1
DOIs
StatePublished - Dec 2020

Keywords

  • SARS-Cov-2
  • antibody neutralization
  • high-throughput neutralization assay
  • neutralizing antibodies
  • serological assay

ASJC Scopus subject areas

  • Immunology

Fingerprint

Dive into the research topics of 'Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS-CoV-2 Neutralizing Antibodies'. Together they form a unique fingerprint.

Cite this